A Phase II Study of Topotecan in Patients with Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study
- 1 May 2001
- journal article
- clinical trial
- Published by Elsevier in Gynecologic Oncology
- Vol. 81 (2) , 213-215
- https://doi.org/10.1006/gyno.2000.6024
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study.Journal of Clinical Oncology, 1997
- Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study.Journal of Clinical Oncology, 1996
- Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma.Journal of Clinical Oncology, 1996
- Phase I Clinical and Pharmacology Study of Topotecan Given Daily for 5 Consecutive Days to Patients With Advanced Solid Tumors, With Attempt at Dose Intensification Using Recombinant Granulocyte Colony-Stimulating FactorJNCI Journal of the National Cancer Institute, 1993
- Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.Journal of Clinical Oncology, 1992
- Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study.Journal of Clinical Oncology, 1985